ITM-11 boosts survival in neuroendocrine tumour trial
A new targeted radiotherapy offers hope for patients with rare neuroendocrine tumours, demonstrating a significant improvement in progression-free survival in a key clinical trial.
List view / Grid view
A new targeted radiotherapy offers hope for patients with rare neuroendocrine tumours, demonstrating a significant improvement in progression-free survival in a key clinical trial.
UVA researchers found that continuous glucose monitor data can predict nerve, eye, and kidney damage in type 1 diabetes.
Explore how FDA’s Project Optimus is reshaping oncology drug dosing strategies, with insights on precision medicine, adaptive trial designs, and the role of CROs in optimising patient outcomes.
Researchers have identified early molecular changes in Rett syndrome that could lead to improved treatments for the condition.
LB Pharmaceuticals announced positive Phase II results for LB-102, showing significant symptom improvement in schizophrenia with a favourable safety profile.
A new study demonstrates how neurotransmitters affect brain gene expression, offering potential therapeutic insights for circadian rhythm disorders.
Learn how Kindeva and Emervax are advancing vaccine delivery with painless, needle-free technology designed to improve accessibility and uptake worldwide.
A Virginia Tech student is investigating new treatments for lupus, an autoimmune disease that affects millions worldwide.
Researchers at the Medical University of South Carolina have discovered a key genetic mechanism that could lead to RNA-based therapies for psychiatric disorders triggered by emotional experiences.
Huntsman Cancer Institute researchers have identified a gene variant in Andean populations that could predict blood cancer treatment outcomes and potentially lead to targeted therapies.
A study from the University of Alabama at Birmingham reveals that HIF1α plays a crucial role in enabling T cells to kill tumour cells under low-oxygen conditions, providing a potential solution to resistance in immune checkpoint blockade (ICB) therapies.
A new peptide-based eye drop treatment for dry AMD offers a non-invasive, effective alternative to injectable therapies, enhancing patient convenience and care.
MIT's new open-source AI model, Boltz-1, could transform drug discovery by accurately predicting protein structures, offering global access to researchers.
Researchers at the University of Chicago have revealed the complete structure of adhesion GPCRs, uncovering new activation mechanisms that could lead to more targeted drug treatments.
New studies highlight the potential of automated blood exchange to improve outcomes for sickle cell disease patients.